Key result
Rivaroxaban was associated with significantly higher reported rates of breakthrough venous thromboembolism, while apixaban had no higher than expected rates of any studied adverse events.
Why the study?
Less is known regarding the long-term side effects of direct oral anticoagulants compared to warfarin at a population level.
Do different direct oral anticoagulants have varying rates of reported adverse events compared to each other and warfarin?
Observational
Do different direct oral anticoagulants have varying rates of reported adverse events compared to each other and warfarin?
Real-world pharmacovigilance data from the FDA suggests differential safety profiles among DOACs, with apixaban showing the most favorable adverse event reporting profile compared to rivaroxaban and dabigatran.
INTRODUCTION: Direct oral anticoagulants (DOACs) are being increasingly used. However, unlike warfarin, less is known regarding their long-term side effects. To better evaluate the rates of DOAC-related adverse events (AEs) on a population level, we examined AEs reported to the FDA for three commonly used DOACs and warfarin. METHODS: We evaluated the FDA Adverse Event Reporting System (FAERS) database, which compiles reported drug-related AEs from 1969 onwards. The safety profiles of the included drugs were assessed by comparing AEs per outpatient prescription and with proportional reporting ratios (PRR). RESULTS: Rivaroxaban had the highest proportion of reported AEs. Most notably the rate for breakthrough venous thromboembolism (VTE) was higher than other DOACs. Dabigatran had the highest reported rates of ischemic stroke. When the DOAC data were analyzed using PRR, reported rates of VTE were again higher with rivaroxaban while dabigatran again showed slightly higher than expected rates of ischemic stroke. Apixaban did not show higher than expected rates in any category. CONCLUSION: Our analysis found rates of reported breakthrough VTE were significantly higher with rivaroxaban, while apixaban had no higher than expected rates of any studied AEs.
No takes yet. Share an insight, caveat, or question.
DeLoughery et al. (2019) conducted an observational in Adverse events related to direct oral anticoagulants and warfarin. Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban) vs. Warfarin and other DOACs was evaluated on Adverse events per outpatient prescription and proportional reporting ratios (PRR). Rivaroxaban was associated with significantly higher reported rates of breakthrough venous thromboembolism, while apixaban had no higher than expected rates of any studied adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: